Skip to main content
Erschienen in: Clinical and Translational Oncology 10/2013

01.10.2013 | Research Article

Expression of p53 upregulated modulator of apoptosis (PUMA) and C-myb in gallbladder adenocarcinoma and their pathological significance

verfasst von: W. Cai, Q. Li, Z. Yang, X. Miao, Y. Wen, S. Huang, J. Ouyang

Erschienen in: Clinical and Translational Oncology | Ausgabe 10/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

An increasing number of studies have shown that PUMA and C-myb signaling pathways are involved in various human cancers including colon carcinomas. However, few studies have examined gallbladder cancer specimens, and little is known about the clinical and pathological significance signaling changes may have in gallbladder adenocarcinoma. This study has investigated the expression of PUMA and C-myb in benign and malignant lesions of gallbladder and its pathological significance.

Methods

Tissue specimens from 108 gallbladder adenocarcinoma patients, 46 adjacent tissues, 15 cases of adenomatous polyps, and 35 surgical specimens from chronic cholecystitis patients were routinely paraffin embedded and sectioned. PUMA and C-myb expressions were detected with EnVision immunohistochemistry.

Results

Positive rates of PUMA and C-myb are significantly higher in gallbladder adenocarcinoma tissues than that in the other three (P < 0.01). Gallbladder epithelial cells in PUMA and/or C-myb positive benign cases manifest moderate to severe atypical dysplasia. Positive rates of PUMA and C-myb in well-differentiated tumors with maximum diameter of <2 cm and with no lymph node metastasis and invasion of the surrounding tissues are significantly lower than that in those poorly differentiated cases with maximum diameter of ≥2 cm, lymph node metastasis, and invasion of the surrounding tissues (P < 0.05 or P < 0.01). The postoperative survival of patients whose tumor specimens are positive for PUMA and C-myb is significantly shorter than that of those who are negative for both markers (P < 0.05 or P < 0.01).

Conclusions

Our results have demonstrated that PUMA and C-myb positive gallbladder tumors progress rapidly, are prone to metastasis, possess strong invasive ability, and have poor prognosis.
Literatur
1.
3.
Zurück zum Zitat Yee KS, Wikinson S, James J, Ryan KM, Vousden KH (2009) PUMA and Bax-induced autophagy contributes to apoptosis. Cell Death Differ 16(8):1135–1145PubMedCrossRef Yee KS, Wikinson S, James J, Ryan KM, Vousden KH (2009) PUMA and Bax-induced autophagy contributes to apoptosis. Cell Death Differ 16(8):1135–1145PubMedCrossRef
4.
Zurück zum Zitat Sinicrope FA, Rego RL, Okumura K, Foster NR, O’Connell MJ, Sargent DJ et al (2008) Prognostic impact of bin, puma, and noxa expression in human colon carcinomas. Clin Cancer Res 14(18):5810–5818PubMedCrossRef Sinicrope FA, Rego RL, Okumura K, Foster NR, O’Connell MJ, Sargent DJ et al (2008) Prognostic impact of bin, puma, and noxa expression in human colon carcinomas. Clin Cancer Res 14(18):5810–5818PubMedCrossRef
5.
Zurück zum Zitat Diallo JS, Aldejmah A, Mouhim AF, Péant B, Fahmy MA, Koumakpayi IH et al (2007) NoXA and PUMA expression add to clinical markers in predicting biochemical recurrence of prostate cancer patients in a survival tree model. Clin Cancer Res 13(23):7044–7052PubMedCrossRef Diallo JS, Aldejmah A, Mouhim AF, Péant B, Fahmy MA, Koumakpayi IH et al (2007) NoXA and PUMA expression add to clinical markers in predicting biochemical recurrence of prostate cancer patients in a survival tree model. Clin Cancer Res 13(23):7044–7052PubMedCrossRef
6.
Zurück zum Zitat Ransay RG, Gonda TJ (2008) MYB function in normal and cancer cells. Nat Rev Cancer 8(7):523–534 Ransay RG, Gonda TJ (2008) MYB function in normal and cancer cells. Nat Rev Cancer 8(7):523–534
7.
Zurück zum Zitat Oh IH, Reddy EP (1999) The myb gene family in cell growth, differentiation and apoptosis. Oncogene 18(19):3017–3033PubMedCrossRef Oh IH, Reddy EP (1999) The myb gene family in cell growth, differentiation and apoptosis. Oncogene 18(19):3017–3033PubMedCrossRef
8.
Zurück zum Zitat Gonda TJ, Leo P, Ramsay RG (2008) Estrogen and MYB in breast cancer: Potential for new therapies. Expert Opin Biol Ther 8(6):713–717PubMedCrossRef Gonda TJ, Leo P, Ramsay RG (2008) Estrogen and MYB in breast cancer: Potential for new therapies. Expert Opin Biol Ther 8(6):713–717PubMedCrossRef
9.
Zurück zum Zitat Wilkins HR, Doucet K, Duke V, Morra A, Johnson N (2010) Estrogen prevents sustained COLO-205 human colon cancer cell growth by inducing apoptosis, decreasing C-myb protein, and decreasing transcription of the anti-apoptosis protein bcl-2. Tumor Biol 31(1):16–22CrossRef Wilkins HR, Doucet K, Duke V, Morra A, Johnson N (2010) Estrogen prevents sustained COLO-205 human colon cancer cell growth by inducing apoptosis, decreasing C-myb protein, and decreasing transcription of the anti-apoptosis protein bcl-2. Tumor Biol 31(1):16–22CrossRef
10.
Zurück zum Zitat Yang H, Huang ZZ, Wang J, Lu SC (2001) The role of C-myb and SP1 in the up-regulation of methionine adenosyltransferase 2A gene expression in human hepatocellular carcinoma. FASEB J 15(9):1507–1516PubMedCrossRef Yang H, Huang ZZ, Wang J, Lu SC (2001) The role of C-myb and SP1 in the up-regulation of methionine adenosyltransferase 2A gene expression in human hepatocellular carcinoma. FASEB J 15(9):1507–1516PubMedCrossRef
11.
Zurück zum Zitat Brabender J, Lord RV, Danenberg KD, Metzger R, Schneider PM, Park JM et al (2001) Increased C-mybmRNA expression in Barrettses ophagusand Barretts-associated adenocarcinoma. J Surg Res 99(2):301–306PubMedCrossRef Brabender J, Lord RV, Danenberg KD, Metzger R, Schneider PM, Park JM et al (2001) Increased C-mybmRNA expression in Barrettses ophagusand Barretts-associated adenocarcinoma. J Surg Res 99(2):301–306PubMedCrossRef
12.
Zurück zum Zitat Nürnberg W, Artuc M, Nawrath M, Lovric J, Stüting S, Moelling K et al (1995) Human C-myb is expressed in cervical carcinomas and transactivates the HPV-16 promoter. Cancer Res 55(19):4432–4437PubMed Nürnberg W, Artuc M, Nawrath M, Lovric J, Stüting S, Moelling K et al (1995) Human C-myb is expressed in cervical carcinomas and transactivates the HPV-16 promoter. Cancer Res 55(19):4432–4437PubMed
13.
Zurück zum Zitat Kim SY, Yang YS, Hong KH, Jang KY, Chung MJ, Lee DY et al (2008) Adenovirus-mediated expression of dominant negative c-myb induces apoptosis in head and neck cancer cells and inhibits tumor growth in animal model. Oral Oncol 44(4):383–392PubMedCrossRef Kim SY, Yang YS, Hong KH, Jang KY, Chung MJ, Lee DY et al (2008) Adenovirus-mediated expression of dominant negative c-myb induces apoptosis in head and neck cancer cells and inhibits tumor growth in animal model. Oral Oncol 44(4):383–392PubMedCrossRef
14.
Zurück zum Zitat Hoque MO, Begum S, Sommer M, Lee T, Trink B, Ratovitski E et al (2003) Puma in head and neck cancer. Cancer Lett 199(1):75–81PubMedCrossRef Hoque MO, Begum S, Sommer M, Lee T, Trink B, Ratovitski E et al (2003) Puma in head and neck cancer. Cancer Lett 199(1):75–81PubMedCrossRef
15.
Zurück zum Zitat Jansson A, Arbman G, San XF (2004) mRNA and protein expression of PUMA in sporadic colorectal cancer. Oncol Rep 12(6):1245–1249PubMed Jansson A, Arbman G, San XF (2004) mRNA and protein expression of PUMA in sporadic colorectal cancer. Oncol Rep 12(6):1245–1249PubMed
Metadaten
Titel
Expression of p53 upregulated modulator of apoptosis (PUMA) and C-myb in gallbladder adenocarcinoma and their pathological significance
verfasst von
W. Cai
Q. Li
Z. Yang
X. Miao
Y. Wen
S. Huang
J. Ouyang
Publikationsdatum
01.10.2013
Verlag
Springer Milan
Erschienen in
Clinical and Translational Oncology / Ausgabe 10/2013
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-013-1010-8

Weitere Artikel der Ausgabe 10/2013

Clinical and Translational Oncology 10/2013 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.